PROTAC 7 achieved 67% oral bioavailability in mice, effectively reduced AR protein and suppresses AR-regulated genes in tumour tissues with oral administration, leading to the effective inhibition of tumour growth in mice without signs of toxicity. This evidence concerns the gene AR and neoplasm.